KONEXFood & Beverage289170

Bioten

₩3,045▲ 14.04%2026-10-02 close

Market Cap

₩10.9B

Turnover

₩3,045

Volume

1 shares

Shares out.

3.6M

PER

—

PBR

—

EPS

—

Dividend Yield

—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

Profitability Must Come First

Bioten, a KONEX-listed micro-cap built on a proprietary curcumin solubilization platform, faces a critical inflection point as revenues have plunged more than 65% from their 2022 peak and operating losses have persisted for three consecutive years.

1
Core technology: WIN-T water-solubilization platform co-developed with KRIBB for poorly soluble natural compounds; domestic and US patents filed on Tenqmin-series materials
2
Revenue collapse and consecutive losses: peak revenue of KRW 10.7bn in 2022 fell to approx. KRW 3.75bn in 2025 (down ~65%), with operating losses recorded in each of the three subsequent years
3
Dual portfolio: nine health functional food materials plus 26 animal supplement products; international market entry ongoing under the proprietary TENQMIN brand in the US, China, and Vietnam
4
Pipeline optionality: pre-clinical stage pipeline covering anti-cancer immunostimulants, obesity/diabetes, and inflammatory bowel disease; obesity treatment composition technology-transfer agreement signed with KRIBB in June 2024
5
Near-zero liquidity: KONEX market structure and broad-based trading volume decline result in essentially zero daily turnover, rendering reliable price discovery unavailable

Business structure

Bioten's core business is the manufacture and sale of nine Tenqmin-S and Tenqmin-G Plus health functional food materials and 26 animal supplement products (Wingten, Blueup, Chamchakan, etc.) based on its WIN-T water-solubilization platform.

The WIN-T technology enhances the bioavailability of poorly water-soluble natural bioactive compounds and was secured via technology-transfer agreements with KRIBB; domestic and US patents have been filed.

The key material 'Tenqmin-S Plus (TSP),' registered with the Ministry of Food and Drug Safety (MFDS) as a food ingredient, provides a degree of exclusivity and regulatory barrier to entry that serves as a competitive differentiator.

The health functional food segment covers human-use materials and finished products, while the animal supplement segment targets companion animals and livestock — together forming a dual-category revenue structure.

The company has launched the proprietary TENQMIN brand to pursue direct overseas market entry in the US, China, Vietnam, and Central Asia, though precise overseas revenue contribution is not verifiable from current disclosures.

On the pharmaceutical side, the company is pursuing pre-clinical research in collaboration with KRIBB across anti-cancer immunostimulants, inflammatory bowel disease, macular degeneration, COVID-19, and obesity/diabetes treatments, with an obesity treatment composition technology-transfer agreement added in June 2024.

Bioten's designation as a KRIBB family enterprise since 2019 provides a structural advantage for continued pipeline access. Production takes place at a company-owned facility in the Jeongup Third Industrial Complex in North Jeolla Province, operated by a workforce of approximately 20 employees.

Both the health functional food and animal supplement markets are highly competitive, with large conglomerate brands and numerous SMEs contending for share, and since curcumin is already handled by many players, sustaining a meaningful price premium for WIN-T-derived materials is the central margin challenge.

Recent trends

In 2022, Bioten posted its all-time best results — revenue of KRW 10.7bn, operating profit of approximately KRW 1.8bn, and net profit of approximately KRW 1.0bn — comfortably satisfying KONEX listing criteria.

However, FY2023 (December year-end) results showed a 49.5% year-on-year revenue decline, with both operating profit and net profit turning negative. According to publicly available financial data, the 2023 operating loss was approximately KRW 450mn and the net loss approximately KRW 610mn.

In 2024, revenue held at roughly KRW 5.49bn — similar to 2023 — while the operating loss widened to approximately KRW 920mn and the net loss deepened to approximately KRW 1.2bn, indicating worsening rather than stabilizing profitability.

In 2025, revenue fell a further 31.6% year-on-year to approximately KRW 3.75bn, with an operating loss of roughly KRW 900mn and a net loss of roughly KRW 830mn continuing the loss trend.

The 2025 revenue of KRW 3.75bn represents a more than 65% contraction from the 2022 peak of KRW 10.7bn over three years; the precise cause — whether the loss of a key customer or the unwinding of concentrated transient demand — cannot be determined from public disclosures alone.

Paid-in capital remained unchanged at KRW 1.85bn between 2024 and 2025, suggesting no external equity financing events occurred during the period.

The share price has fallen from the KRW 8,000 initial evaluation price at the October 2023 KONEX listing to KRW 3,085 currently, reflecting the post-listing deterioration in financial results. With just one share traded on the reference date (daily turnover: KRW 3,085), meaningful price discovery is effectively absent.

Outlook

In the near term, a rebound in core health food and animal supplement revenues is the key to earnings recovery; however, with three consecutive years of operating losses, the visibility of a short-term turnaround is limited.

Over the medium to long term, pre-clinical readouts from the obesity/diabetes and anti-cancer immunostimulant pipelines pursued jointly with KRIBB could serve as meaningful catalysts, though the timeline to clinical entry — and associated costs — remains substantial.

Successful penetration of overseas markets under the TENQMIN brand could unlock additional revenue channels, but the distribution network is still at an early stage and a material sales contribution has no clearly defined timeline.

The domestic health functional food market continues to benefit from aging demographics and wellness trends, providing a structurally supportive long-run demand environment.

While a KOSDAQ transfer is stated as a long-term strategic objective, the near-absence of recent KONEX-to-KOSDAQ transitions and the rapid deterioration of KONEX market liquidity create a challenging backdrop for that ambition.

Revenue growth and a return to operating profitability are prerequisites for both financial sustainability and meeting KOSDAQ listing criteria; if current loss trends persist, the risk of deepening accumulated deficits will intensify.

Bull factors

KRIBB-Backed Proprietary Ingredient Platform

The WIN-T water-solubilization platform, secured through joint research and technology-transfer agreements with KRIBB, enhances the bioavailability of poorly soluble natural compounds and is protected by domestic and international patent filings, establishing a partial replication barrier.

The key material TSP is registered with the MFDS, providing a regulatory moat, and its scientific credibility was bolstered by a publication in the International Immunopharmacology journal in February 2023.

Bioten's KRIBB family enterprise status affords continued access to new technology-transfer opportunities — as demonstrated by the June 2024 obesity treatment composition licensing deal.

The ability to apply the same platform technology across food, feed, and pharmaceutical applications provides platform extensibility that carries meaningful medium-to-long-term option value.

Dual Revenue Base and Export Upside

The dual portfolio of nine health functional food products and 26 animal supplement lines provides partial diversification against single-category demand risk.

Direct overseas market entry under the TENQMIN brand across the US, China, Vietnam, and Central Asia offers meaningful export upside should market penetration accelerate, helping to offset domestic market headwinds.

Global structural demand trends for health functional foods and pet-care products remain favorable, supporting the long-run demand premise. The lean organizational structure of roughly 20 employees keeps the cost base manageable, and an eventual revenue recovery could deliver rapid operating leverage.

Long-Term Option Value in the Pharmaceutical Pipeline

The pre-clinical pipeline spanning anti-cancer immunostimulants, obesity/diabetes treatments, inflammatory bowel disease, and macular degeneration represents potential value not yet captured in current revenues.

If the company successfully expands into human and veterinary pharmaceuticals, a significant valuation re-rating relative to the current food/supplement revenue base is conceivable.

The publication of a COVID-19 treatment potential study in the International Immunopharmacology journal provides limited but tangible external validation of the core material's pharmacological potential.

That said, the pre-clinical stage entails a long road to commercialization, and a high discount rate must be applied to pipeline valuation at the current stage of development.

Bear factors

Sharp Revenue Decline and Persistent Operating Losses

Revenue collapsed from KRW 10.7bn in 2022 to approximately KRW 3.75bn in 2025 — a decline of more than 65% in just three years — accompanied by three consecutive years of operating losses.

The operating loss widened from roughly KRW 450mn in 2023 to KRW 920mn in 2024 before stabilizing around KRW 900mn in 2025, suggesting that no meaningful structural cost improvement has been achieved.

The precise drivers of the revenue collapse are not clearly explained in public disclosures, making it difficult to form a reasonable view on the timing or nature of a recovery.

Continued accumulation of deficits heightens the probability of capital impairment and a growing need for external financing, creating a risk of financial deterioration feedback loop.

Extreme Illiquidity on the KONEX Market

As of the reference date (June 7, 2026), only a single share was traded for a total turnover of KRW 3,085, rendering the market effectively illiquid and making position entry or exit practically impossible.

According to recent media reports, the KONEX market average daily trading volume in 2026 has declined 30.9% versus 2024, indicating structural deterioration of the venue itself.

Such extreme illiquidity means even minimal transactions can trigger sharp price swings, creating a persistent volatility risk while preventing the company's growth or technology value from being adequately reflected in the share price. The longer a KOSDAQ transfer is delayed, the deeper the structural liquidity discount becomes.

Execution Constraints of a Micro-Scale Organization

An organization of roughly 20 employees is structurally constrained in its capacity to simultaneously pursue R&D, production, domestic sales, overseas market development, and clinical advancement of pharmaceutical pipeline candidates.

Advancing the obesity/diabetes treatment and other pharmaceutical candidates to clinical stages would require investment far exceeding current resources and organizational bandwidth, making external partnerships or financing essential. The departure of key technical personnel — notably CTO Dr.

Lee Woo-song — could disrupt technological continuity given the concentrated nature of the knowledge base. Pursuing multiple strategic fronts simultaneously on an annual revenue base of KRW 3.75bn risks resource dilution and loss of execution focus.

Risk factors

Macro & Consumer Spending Risk

A domestic and global economic slowdown and associated consumer spending contraction could dampen demand for premium health functional food ingredients; as a micro-cap, Bioten has limited pricing power and channel access relative to larger peers, reducing its shock-absorption capacity.

Fluctuations in the supply and pricing of curcumin as a natural raw material directly affect cost structure, with additional foreign-exchange risk if overseas sourcing is involved.

Rising global protectionism and tightening regulatory requirements for health products in target export markets add uncertainty to the pace and cost of the TENQMIN brand's international expansion.

Business & Competition Risk

The health functional food and animal supplement markets are highly competitive, with large conglomerate brands and numerous SMEs contending for share; curcumin is a commodity ingredient handled by many players, and sustaining a meaningful price premium for WIN-T-derived materials cannot be assumed.

Revenue concentration around a small number of key customers or ODM partners creates significant downside risk upon customer departure — a factor likely to have contributed to the sharp revenue decline from 2023 onward.

Over the long term, expanding into human and veterinary pharmaceuticals introduces a new competitive landscape with clinical-stage rivals and a significantly more stringent regulatory environment.

Financial & Liquidity Risk

Three consecutive years of operating losses alongside sharply declining revenue are gradually heightening the risk of working capital depletion and capital impairment, both of which would further delay meeting the financial prerequisites for a KOSDAQ listing.

If external financing is needed for R&D expansion or overseas sales investment, the near-zero liquidity of the KONEX market makes equity issuance through rights offerings practically unfeasible.

Continued net losses will accumulate retained deficits that progressively erode shareholders' equity, intensifying the structural financial risk over time.

Overall view

Bioten possesses a meaningful qualitative asset base — a KRIBB-backed proprietary solubilization platform, a dual product portfolio, and pharmaceutical pipeline optionality — which provides some foundation for long-term growth potential.

However, the more-than-65% revenue contraction from the 2022 peak, three consecutive years of operating losses, and a materially weakened balance sheet compel a cautious assessment.

The structural reality of near-zero daily trading on KONEX means price discovery and position exit are functionally unavailable, constituting a permanent liquidity risk that cannot be diversified away.

Until credible signals of revenue recovery and a return to operating profitability emerge, financial uncertainty remains elevated, and the prospect of a near-term KOSDAQ transfer is limited given current market conditions.

Over a longer horizon, demonstrable progress in the KRIBB pipeline or visible TENQMIN overseas revenues could create re-rating potential, but the timing and magnitude of such catalysts cannot be reliably estimated at this stage.

This report is prepared solely for informational purposes and does not constitute a recommendation to buy or sell any security.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 5 more articles and sources

Report written 2026-06-08 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.